2015-06-03 18:57:20 UTC

New Developments in Hepatitis B

Clinical Snapshots

About

This AGA Clinical Snapshot is an executive summary of Dr. Lok's presentation during the 2015 AGA Spring Postgraduate Course at DDW® 2015 in Washington, DC.

Clinical snapshots are free to AGA members. Please log in and "purchase" the free module to add it to your account. You will then have access to the full content of the summary on this same page whenever you are logged into the website.

Takeaways

1. Learn efficacy and limitations of currently approved treatments for hepatitis B.

2. Understand when to start and when to stop treatment.

3. Learn about the prospects for a cure.

About the Instructors

Anna S.F. Lok, MD, AGAF, University of Michigan

This is only a preview. Full access is reserved for AGA members. Login or learn more about becoming a member.

Efficacy and Limitations of Currently Approved Treatments

There are seven approved therapies: two formulations of interferon and five nucleos/tide analogues: lamivudine, telbivudine, entecavir, adefovir and tenofovir 1, 2. Although these drugs are effective in suppressing hepatitis B virus (HBV) replication, the rates of clearance of hepatitis B e antigen (HBsAg) and hepatitis B surface antigen (HBsAg) are low. Nevertheless, antiviral therapy for hepatitis B had been shown not only to reduce hepatic inflammation but also to reverse fibrosis and even cirrhosis …

More on Hepatitis C

Attend the AGA Postgraduate Course for Practical, Take Home Information

Feb. 12, 2018

Join us on June 2-3 in Washington, D.C. This course is held in conjunction with Digestive Disease Week® (DDW) 2018.

Medicaid Skimps on Hepatitis C Treatment in Many States

Feb. 8, 2018

Report finds restrictions based on liver disease severity, sobriety and type of provider.

Image Challenge: Cullen's Sign

Jan. 22, 2018

What caused a 56-year-old man with a previous history of cirrhosis to present with a large volume of ascites and periumbilical ecchymosis?